<DOC>
	<DOC>NCT01420510</DOC>
	<brief_summary>We hypothesise that the use of Adelmidrol (Saginil in vaginal cannulas) can reduce the incidence and magnitude of vaginitis in patients affected by gynecologic malignancies.</brief_summary>
	<brief_title>Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis</brief_title>
	<detailed_description />
	<mesh_term>Vaginitis</mesh_term>
	<criteria>Gynecologic malignancy Current administration of chemotherapy Colpectomy Vaginal cancer Vulvar cancer Bacterial vaginitis</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Patients satisfaction</keyword>
	<keyword>Side effects</keyword>
</DOC>